Innovent Biopharmaceutical Technology (hangzhou) Co., Ltd.

This early-stage trial is testing a new drug called IBI3028 in people with advanced solid tumors that cannot be removed by surgery or have spread. The drug works by attaching to two proteins (EGFR and c-Met) found on some cancer cells and delivering two anti-cancer agents directl…

This study tests a combination of two drugs, IBI310 and sintilimab, as a first treatment for people with advanced liver cancer that cannot be removed by surgery. About 680 participants will receive either the combination or standard care. The goal is to see if the combination shr…

This study tests a new drug called picankibart for people with active psoriatic arthritis, a condition causing joint pain and skin plaques. About 222 adults will get either the drug or a placebo for 24 weeks to see if it improves joint swelling and tenderness. The goal is to find…

This phase 3 study tests a new drug called IBI354, given alone or with another drug (pertuzumab), against the current standard treatment for people with advanced HER2-positive breast cancer that cannot be removed by surgery. The trial aims to see if the new combination can delay …

This study tests a drug called picankibart in teenagers aged 12 to 18 with moderate-to-severe plaque psoriasis. Half get the drug, half get a placebo, and researchers check if their skin clears up after 16 weeks. The goal is to see if it's safe and works better than a dummy treat…